392 related articles for article (PubMed ID: 24588504)
1. MRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge.
Jacobsen CO; Farbu E
Acta Neurol Scand Suppl; 2014; (198):32-6. PubMed ID: 24588504
[TBL] [Abstract][Full Text] [Related]
2. Challenges in multiple sclerosis; how to define occurence of progression.
Brinar VV; Barun B
Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S30-4. PubMed ID: 24321151
[TBL] [Abstract][Full Text] [Related]
3. Grey matter pathology in clinically early multiple sclerosis: evidence from magnetic resonance imaging.
Chard D; Miller D
J Neurol Sci; 2009 Jul; 282(1-2):5-11. PubMed ID: 19201002
[TBL] [Abstract][Full Text] [Related]
4. Cortical lesion load associates with progression of disability in multiple sclerosis.
Calabrese M; Poretto V; Favaretto A; Alessio S; Bernardi V; Romualdi C; Rinaldi F; Perini P; Gallo P
Brain; 2012 Oct; 135(Pt 10):2952-61. PubMed ID: 23065788
[TBL] [Abstract][Full Text] [Related]
5. Gray matter atrophy in multiple sclerosis: a longitudinal study.
Fisher E; Lee JC; Nakamura K; Rudick RA
Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
[TBL] [Abstract][Full Text] [Related]
6. Comparison of grey matter atrophy between patients with neuromyelitis optica and multiple sclerosis: a voxel-based morphometry study.
Duan Y; Liu Y; Liang P; Jia X; Yu C; Qin W; Sun H; Liao Z; Ye J; Li K
Eur J Radiol; 2012 Feb; 81(2):e110-4. PubMed ID: 21316170
[TBL] [Abstract][Full Text] [Related]
7. Evidence for gray matter pathology in multiple sclerosis: a neuroimaging approach.
Zivadinov R; Minagar A
J Neurol Sci; 2009 Jul; 282(1-2):1-4. PubMed ID: 19345379
[TBL] [Abstract][Full Text] [Related]
8. Brain atrophy and lesion load in a large population of patients with multiple sclerosis.
Tedeschi G; Lavorgna L; Russo P; Prinster A; Dinacci D; Savettieri G; Quattrone A; Livrea P; Messina C; Reggio A; Bresciamorra V; Orefice G; Paciello M; Brunetti A; Coniglio G; Bonavita S; Di Costanzo A; Bellacosa A; Valentino P; Quarantelli M; Patti F; Salemi G; Cammarata E; Simone IL; Salvatore M; Bonavita V; Alfano B
Neurology; 2005 Jul; 65(2):280-5. PubMed ID: 16043800
[TBL] [Abstract][Full Text] [Related]
9. Gray matter involvement in multiple sclerosis.
Pirko I; Lucchinetti CF; Sriram S; Bakshi R
Neurology; 2007 Feb; 68(9):634-42. PubMed ID: 17325269
[TBL] [Abstract][Full Text] [Related]
10. Sodium accumulation is associated with disability and a progressive course in multiple sclerosis.
Paling D; Solanky BS; Riemer F; Tozer DJ; Wheeler-Kingshott CA; Kapoor R; Golay X; Miller DH
Brain; 2013 Jul; 136(Pt 7):2305-17. PubMed ID: 23801742
[TBL] [Abstract][Full Text] [Related]
11. Clinical and imaging metrics for monitoring disease progression in patients with multiple sclerosis.
Bagnato F; Ohayon JM; Ehrmantraut M; Chiu AW; Riva M; Ikonomidou VN
Expert Rev Neurother; 2006 Apr; 6(4):599-612. PubMed ID: 16623658
[TBL] [Abstract][Full Text] [Related]
12. The neurologist's dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately--no.
Filippi M; Rocca MA
Mult Scler; 2012 May; 18(5):557-8. PubMed ID: 22547411
[No Abstract] [Full Text] [Related]
13. Fractal dimension analysis of grey matter in multiple sclerosis.
Esteban FJ; Sepulcre J; de Miras JR; Navas J; de Mendizábal NV; Goñi J; Quesada JM; Bejarano B; Villoslada P
J Neurol Sci; 2009 Jul; 282(1-2):67-71. PubMed ID: 19167728
[TBL] [Abstract][Full Text] [Related]
14. The neurologist's dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately--yes.
Geurts JJ
Mult Scler; 2012 May; 18(5):559-60. PubMed ID: 22547412
[No Abstract] [Full Text] [Related]
15. Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI.
Amiri H; de Sitter A; Bendfeldt K; Battaglini M; Gandini Wheeler-Kingshott CAM; Calabrese M; Geurts JJG; Rocca MA; Sastre-Garriga J; Enzinger C; de Stefano N; Filippi M; Rovira Á; Barkhof F; Vrenken H;
Neuroimage Clin; 2018; 19():466-475. PubMed ID: 29984155
[TBL] [Abstract][Full Text] [Related]
16. Focal thinning of the cerebral cortex in multiple sclerosis.
Sailer M; Fischl B; Salat D; Tempelmann C; Schönfeld MA; Busa E; Bodammer N; Heinze HJ; Dale A
Brain; 2003 Aug; 126(Pt 8):1734-44. PubMed ID: 12805100
[TBL] [Abstract][Full Text] [Related]
17. Contribution of white matter lesions to gray matter atrophy in multiple sclerosis: evidence from voxel-based analysis of T1 lesions in the visual pathway.
Sepulcre J; Goñi J; Masdeu JC; Bejarano B; Vélez de Mendizábal N; Toledo JB; Villoslada P
Arch Neurol; 2009 Feb; 66(2):173-9. PubMed ID: 19204153
[TBL] [Abstract][Full Text] [Related]
18. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study.
Jacobsen C; Hagemeier J; Myhr KM; Nyland H; Lode K; Bergsland N; Ramasamy DP; Dalaker TO; Larsen JP; Farbu E; Zivadinov R
J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1109-15. PubMed ID: 24554101
[TBL] [Abstract][Full Text] [Related]
19. Gray matter damage in multiple sclerosis: Impact on clinical symptoms.
van Munster CE; Jonkman LE; Weinstein HC; Uitdehaag BM; Geurts JJ
Neuroscience; 2015 Sep; 303():446-61. PubMed ID: 26164500
[TBL] [Abstract][Full Text] [Related]
20. Brain volumetry counterparts of cognitive impairment in patients with multiple sclerosis.
Sastre-Garriga J; Arévalo MJ; Renom M; Alonso J; González I; Galán I; Montalban X; Rovira A
J Neurol Sci; 2009 Jul; 282(1-2):120-4. PubMed ID: 19157420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
